Clinical Research

JJCCC is one of the primary institutions that comprise the Children’s Oncology Group (COG), an international, cooperative childhood cancer research network that focuses on identifying cancer causes and pioneering new treatments and cures at children’s hospitals. With COG, Miller Children’s enrolls patients on Phase II and III clinical trials. Participation in COG advances research and allows JJCCC to offer the latest and most effective treatments to young patients. JJCCC manages most of the leukemia, brain tumors and bone tumor studies.    

JJCCC has more than 50 open studies and enrolls more than 75 percent of their patients in clinical trials. JJCCC actively participates in the Therapeutic Advances in Childhood Leukemia (TACL) studies, a consortium that carries out early studies of new drugs in children with recurrent leukemia. The TACL studies are Phase I and II. The phase III may or may not be randomized controlled trials on large patient population depending upon the disease/medical condition studied. They are aimed at being the definitive assessment on how effective the drug is in comparison with current standard treatment.

Open TACL Studies

• Therapeutic Advance in Childhood Leukemia (CHLA Study)
  2006-002 Intravenous Erwinia for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and allergic to E. coli Asparaginase
• Bristol-Myers
  Phase II study with Dasatinib in Ph+ Leukemia in children and adolescents
• HEAD START III:
  A Dose Intensive Chemotherapy for Children less than 10 years of age newly-diagnosed with malignant brain tumor: A pilot study of two alternative intensive induction chemotherapy regimens, followed by consolidation with myeloablative chemotherapy ( Thiotepa and carboplatin, with or without Etoposide) and Autologous stem cell rescue (CHLA Study)